Pharmacy Times just released within the hour that the FDA has approved a treatment for moderate-severe Atopic Dermatitis. The drug is called Dupixent and it's an injection for patients that are unable to control the dermatitis with a topical cream.
Jennifer Barrett writes, "The FDA’s approval is based on data from the global LIBERTY AD clinical
program, which included 3, phase 3 trials that examined the use of
Dupixent either alone or with topical corticosteroids in patients with
inadequately controlled moderate-to-severe AD. Dupixent alone or with
topical corticosteroids met its primary and key secondary endpoints in
all trials."
Learn more about this new drug by reading the full article HERE!
Performance Pharmacy Solutions (PPS) is a unique pharmacy benefit procurement platform developed by HORIZON Health Ventures to
efficiently and effectively place, manage and oversee our self-funded
client's pharmacy benefit management programs. The PPS platform provides
turnkey solutions with proven market-leading PBM partners that offer,
on average, 10-15% savings.
No comments:
Post a Comment